Deal Snapshot
Turnstone Biologics Acquires Myst Therapeutics to Expand Biotechnology Portfolio
Thursday 21 January 2021

New York-based clinical-stage biotechnology company Turnstone Biologics Corp. has acquired California-based biotechnology company Myst Therapeutics to add proprietary tumor infiltrating lymphocyte (TIL) technology and programmes to Turnstone's growing portfolio, the company said.

The acquisition adds a pipeline of innovative TIL programmes to Turnstone's portfolio of oncolytic virus candidates. Myst has focussed on applying their innovative T-cell selection strategies to clinically proven TIL treatment protocols. With this acquisition, Turnstone gains full access Myst's T-cell selection strategies to TIL treatment protocols.

Date Published: 21/01/2021